World J Oncol

World Journal of Oncology, ISSN 1920-4531 print, 1920-454X online, Open Access

Article copyright, the authors; Journal compilation copyright, World J Oncol and Elmer Press Inc

Journal website https://wjon.elmerpub.com

Original Article

Volume 16, Number 1, February 2025, pages 95-103

Impact of 2021 World Health Organization Grading, Peritumoral Edema, and Radiotherapy on the Recurrence of a Grossly Resected Intracranial Meningiomas: A Ten-Year Follow-Up Study

↓ Figure 1. Decision tree of the 124 patients enrolled in this study was segregated by sex, tumor location, WHO grading, treatment, and recurrence-free interval (RFI). WHO: World Health Organization; RT: radiotherapy.

↓ Figure 2. The relationship between WHO grading and RFI among all 124 patients with intracranial meningiomas. RFI: recurrence-free interval; WHO: World Health Organization.

↓ Figure 3. The relationship between peritumoral edema (PTE) and RFI among all 124 patients with intracranial meningiomas. RFI: recurrence-free interval.

↓ Figure 4. Peritumoral edema (PTE) around the intracranial meningioma. The left image is created using an artificial intelligence (AI) program, ChatGPT 4-DALL 2 plus.

↓ **Table 1.** Characteristics of 124 Patients With Intracranial Meningioma
	Overall (n = 124)
WHO: World Health Organization.
Age at diagnosis
Mean (SD)	49.0 (13.2)
Range	18.0 - 84.0
Sex
Female	87 (70.2%)
Male	37 (29.8%)
Tumor location
Supratentorial	110 (88.7%)
Infratentorial	14 (11.3%)
Presence of peritumoral edema (PTE)
Present	76 (61.3%)
Not present	48 (38.7%)
2021 WHO grading
Grade I	101 (81.5%)
Grade II	17 (13.7%)
Grade III	6 (4.8%)
Histological subtype
Meningothelial	93 (75.0%)
Fibrous	4 (3.2%)
Angiomatous	2 (1.6%)
Secretory	1 (0.8%)
Microcystic	1 (0.8%)
Atypical	16 (12.9%)
Chordoid	1 (0.8%)
Anaplastic	2 (1.6%)
Rhabdoid	4 (3.2%)
Post-surgical treatment
Radiotherapy (RT)	19 (15.3%)
Tumor recurrence
No recurrence	103 (83.1%)
Recurrence	21 (16.9%)
Survival status
Survived	118 (95.2%)
Died	6 (4.8%)

↓ Table 1. Characteristics of 124 Patients With Intracranial Meningioma

Overall (n = 124)

WHO: World Health Organization.

Age at diagnosis

Mean (SD)

49.0 (13.2)

Range

18.0 - 84.0

Sex

Female

87 (70.2%)

Male

37 (29.8%)

Tumor location

Supratentorial

110 (88.7%)

Infratentorial

14 (11.3%)

Presence of peritumoral edema (PTE)

Present

76 (61.3%)

Not present

48 (38.7%)

2021 WHO grading

Grade I

101 (81.5%)

Grade II

17 (13.7%)

Grade III

6 (4.8%)

Histological subtype

Meningothelial

93 (75.0%)

Fibrous

4 (3.2%)

Angiomatous

2 (1.6%)

Secretory

1 (0.8%)

Microcystic

1 (0.8%)

Atypical

16 (12.9%)

Chordoid

1 (0.8%)

Anaplastic

2 (1.6%)

Rhabdoid

4 (3.2%)

Post-surgical treatment

Radiotherapy (RT)

19 (15.3%)

Tumor recurrence

No recurrence

103 (83.1%)

Recurrence

21 (16.9%)

Survival status

Survived

118 (95.2%)

Died

6 (4.8%)

↓ **Table 2.** The Relationship Between Patients’ Age, 2021 WHO Grading, and the Recurrence Rate Among 124 Meningioma Cases
	No recurrence (n = 103, 83.1%)	Recurrence (n = 21, 16.9%)	Total (n = 124)	P value
WHO: World Health Organization; SD: standard deviation.
Age at diagnosis, mean (SD)	48.7 (13.3%)	50.4 (12.8%)	49.0 (13.2)	0.594
WHO grading
Grade I	93 (90.3%)	8 (38.1%)	101 (81.5)	< 0.001
Grade II	9 (8.7%)	8 (38.1%)	17 (13.7)
Grade III	1 (1.0%)	5 (23.8%)	6 (4.8)

↓ Table 2. The Relationship Between Patients’ Age, 2021 WHO Grading, and the Recurrence Rate Among 124 Meningioma Cases

No recurrence (n = 103, 83.1%)

Recurrence (n = 21, 16.9%)

Total (n = 124)

P value

WHO: World Health Organization; SD: standard deviation.

Age at diagnosis, mean (SD)

48.7 (13.3%)

50.4 (12.8%)

49.0 (13.2)

0.594

WHO grading

Grade I

93 (90.3%)

8 (38.1%)

101 (81.5)

< 0.001

Grade II

9 (8.7%)

8 (38.1%)

17 (13.7)

Grade III

1 (1.0%)

5 (23.8%)

6 (4.8)